The maximum amount that any participant may save per month under the plan is £250.00, whichmust be determined and fixed on enrollment in the plan.In the event of a variation of share capital by way of capitalization, rights issue, sub-division,consolidation or reduction of share capital, then the number of <strong>Xyratex</strong> Ltd common shares subject toa subsisting option and the price payable on exercise may be adjusted. No adjustment can be made tooptions granted under the Sharesave Plan without prior Inland Revenue approval.Our board of directors may alter the plans, but no alteration will have effect under the SharesavePlan without prior U.K. Inland Revenue approval. The provisions relating to shareholder approval foramendments are as the <strong>Xyratex</strong> Ltd Approved Plan.None of the benefits which may be received under the Sharesave Plan shall be pensionable.The Sharesave Plan was approved by our shareholders at our annual general meeting ofshareholders on April 13, 2005.The 2004 PlanThe 2004 Plan is a U.S. stock option plan under which we may grant incentive stock options topurchase our shares to our employees and nonqualified stock options to purchase our shares to ouremployees, consultants and non-employee officers and directors.The per share exercise price of an incentive stock option may not be less than the fair marketvalue of one of our common shares on the date of grant (and not less than 110% of the fair marketvalue in the case of incentive stock options granted to holders of our shares possessing more than 10%of the voting power of all classes of our then outstanding shares). Initially, the per share exercise priceof a nonqualified stock option will not be restricted, but all nonqualified stock options granted after aspecified period and for so long as <strong>Xyratex</strong> Ltd is a publicly held corporation will be required to have aper share exercise price of not less than the fair market value of our common shares on the date ofgrant. An option may not be exercised more than ten years after the date of grant. Under the 2004Plan, an option granted to an employee, consultant, officer or director will terminate if employment orservice terminates. The maximum number of shares we can issue under the 2004 Plan is 5,000,000,provided that the limits set forth above in ‘‘Management—Employee Benefit/Share Option Plans—<strong>Xyratex</strong> Ltd Share Option and Share Purchase Plans’’ shall apply.Under the 2004 Plan, if any of certain specified types of transactions occurs, for example if weamalgamate with another entity, then, depending on the transaction, we may or will be required to(i) arrange for the substitution of options on equity securities other than our common shares inexchange for outstanding options, (ii) accelerate the vesting and termination of outstanding options, inwhole or in part, or (iii) cancel outstanding options in exchange for cash payments.The Employee Stock Purchase PlanThe Employee Stock Purchase Plan, or ESPP, is a U.S. employee stock purchase plan under whicheligible employees of any of our designated subsidiaries who elect to participate will receive rights topurchase our shares on favorable terms and with U.S. federal income tax advantages throughaccumulated payroll deductions.The sole initial designated subsidiary is <strong>Xyratex</strong> International, Inc. Our board of directors maychange the designated subsidiaries from time to time.Each participant who enrolls in the ESPP for an offering period will receive a purchase right. Apurchase right entitles a participant to purchase at the end of each offering period the number of ourcommon shares determined by dividing the participant’s accumulated payroll deductions in his or herplan account by the purchase price for that offering period. Generally, the per share purchase price of70
the shares subject to a purchase right for an offering period is 85% of the lower of the fair marketvalue of one of our common shares on the first trading day of the offering period or the fair marketvalue of such a share on the last trading day of the offering period. Generally, the fair market value ofone of our common shares on any date will be the closing price of such a share on the NASDAQNational Market on that date.Any individual (except any employee who owns shares possessing 5% or more of the voting poweror value of all classes of our issued shares or the shares of any of our subsidiaries) will be eligible toparticipate in the ESPP for an offering period if he or she both (i) was employed by a designatedsubsidiary throughout a specified period ending on the first trading day of such offering period, and(ii) is customarily employed, as of such day, by a designated subsidiary for at least 20 hours per weekand for at least five months per calendar year.The maximum fair market value of our common shares that any participant may purchase underthe plan during any calendar year is $25,000, determined on the first trading day of the offering period.The initial number of our shares reserved for issuance pursuant to purchase rights to be grantedunder the ESPP is 100,000. On each December 1, beginning December 1, 2004, there will automaticallybe added to the number of shares reserved under the plan the least of (i) 500,000, (ii) 1% of thenumber of our common shares outstanding on that date or (iii) such other number of our commonshares as our board of directors determines.In the event of a sale of substantially all of our assets, or in the event we amalgamate with anothercorporation or we liquidate or dissolve, or in the event of any other transaction as a result of whichother shares are substituted for our common shares or our common shares may no longer be issued,our board will provide for the assumption or substitution of purchase rights by the successor orsurviving corporation or a parent or subsidiary or take such other action as it deems appropriate.Subject to the approval of our shareholders as to certain types of amendments, our board ofdirectors may modify, amend, alter or terminate the ESPP, including amending or terminating any orall outstanding purchase rights, at any time.2004 Directors Stock Option Plan<strong>Xyratex</strong> Ltd adopted a 2004 Directors Stock Option Plan for the purpose of making one-timegrants of options to purchase 20,000 <strong>Xyratex</strong> Ltd common shares to each of Ernest Sampias, SteveSanghi and Jonathan Brooks. The non-qualified stock options were granted effective June 29, 2004 andthe exercise price of the options is $14.00 per share, equal to the initial public offering price of ourcommon shares. The options will vest as to 25% of the shares on each November 30 in 2004 through2007. An option may not be exercised after the option holder ceases to be a director of <strong>Xyratex</strong> Ltd forany reason or no reason, or more than ten years after the date of grant. The maximum number ofshares we can issue under the plan is 60,000 shares.Deputy Chairman’s Stock Option Plan<strong>Xyratex</strong> Ltd made a one-time grant of options to purchase 228,003 <strong>Xyratex</strong> Ltd common shares toMr. Sukawaty, who at the time of grant was Deputy Chairman of the Company. The unapproved stockoptions were granted effective March 31, 2004 and the exercise price of the options is $14.47 per share.The options will vest as to 25% of the shares on each November 30 in 2004 through 2007. An optionmay not be exercised after the option holder ceases to be a director of <strong>Xyratex</strong> Ltd for any reason orno reason, or more than ten years after the date of grant. The maximum number of shares we canissue under the plan is 228,003 shares.71
- Page 3:
XYRATEX LTDANNUAL REPORT FOR THE YE
- Page 6 and 7:
INTRODUCTIONWe are incorporated und
- Page 8 and 9:
Year Ended November 30,2005 2004 20
- Page 10 and 11:
The computations for the weighted a
- Page 12 and 13:
The markets in which we operate are
- Page 14 and 15:
technological capabilities. This co
- Page 16 and 17:
may cease production of components,
- Page 18 and 19:
• potentially adverse tax consequ
- Page 20 and 21:
We could incur substantial costs, i
- Page 22 and 23:
influence by voting at a meeting of
- Page 24 and 25: Xyratex Ltd to the former sharehold
- Page 26 and 27: In addition to the rapid growth of
- Page 28 and 29: RAID controller technology is proje
- Page 30 and 31: Our Competitive StrengthsDisk drive
- Page 32 and 33: the storage subsystem and disk driv
- Page 34 and 35: Our storage subsystems are internal
- Page 36 and 37: systems are capable of testing a fu
- Page 38 and 39: Research and DevelopmentWe have ove
- Page 40 and 41: • sets forth procedures for the p
- Page 42 and 43: Item 4C: Organization StructureXyra
- Page 44 and 45: ecame the parent company of our bus
- Page 46 and 47: Foreign Exchange Rate FluctuationsT
- Page 48 and 49: we recorded in the year ended Novem
- Page 50 and 51: Fiscal Year Ended November 30, 2005
- Page 52 and 53: Research and Development—otherThe
- Page 54 and 55: Fiscal Year Ended November 30, 2004
- Page 56 and 57: Selling, General and Administrative
- Page 58 and 59: Quarterly Results of OperationsThe
- Page 60 and 61: sales growth. The increase in defer
- Page 62 and 63: choose to make or alliances we have
- Page 64 and 65: compete. Identifiable intangible as
- Page 66 and 67: ITEM 6: DIRECTORS, SENIOR MANAGEMEN
- Page 68 and 69: Ernest Sampias has served as a dire
- Page 70 and 71: Audit CommitteeOur Audit Committee
- Page 72 and 73: Employee Benefit/Share Option Plans
- Page 76 and 77: Restricted StockRestricted stock aw
- Page 78 and 79: the options, warrants or rights, bu
- Page 80 and 81: Quarterly high and low market price
- Page 82 and 83: whose functional currency is not th
- Page 84 and 85: on the Nasdaq National Market and,
- Page 86 and 87: Interest RatesWe had cash and cash
- Page 88 and 89: aggregate in any fiscal year and th
- Page 90 and 91: (This page has been left blank inte
- Page 92 and 93: XYRATEX LTDAUDITED CONSOLIDATED BAL
- Page 94 and 95: F-4XYRATEX LTDAUDITED CONSOLIDATED
- Page 96 and 97: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 98 and 99: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 100 and 101: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 102 and 103: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 104 and 105: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 106 and 107: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 108 and 109: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 110 and 111: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 112 and 113: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 114 and 115: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 116 and 117: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 118 and 119: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 120 and 121: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 122 and 123: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 124 and 125:
XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 126 and 127:
XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 128 and 129:
XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 130:
(This page has been left blank inte